Moderna, Inc. Deferred Income Tax Expense (Benefit)
Moderna, Inc. (MRNA) reported Deferred Income Tax Expense (Benefit) of $10.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-02-20
- Moderna, Inc. deferred income tax expense (benefit) for the quarter ending 2022-12-31 was -$105.00M.
- Moderna, Inc. deferred income tax expense (benefit) for the quarter ending 2022-09-30 was -$97.00M.
- Moderna, Inc. deferred income tax expense (benefit) for the quarter ending 2022-06-30 was -$230.00M.
- Moderna, Inc. deferred income tax expense (benefit) for the quarter ending 2022-03-31 was -$146.00M.
- Moderna, Inc. deferred income tax expense (benefit) for fiscal 2025 was $10.00M.
- Moderna, Inc. deferred income tax expense (benefit) for fiscal 2024 was -$1.00M, a 100.11% decline from fiscal 2023.
- Moderna, Inc. deferred income tax expense (benefit) for fiscal 2023 was $901.00M.
- Moderna, Inc. deferred income tax expense (benefit) for fiscal 2022 was -$578.00M.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month | Deferred Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $10.00M 10-K · filed 2026-02-20 | ||||
| 2024-12-31 | -$1.00M 10-K · filed 2026-02-20 | ||||
| 2023-12-31 | $901.00M 10-K · filed 2026-02-20 | ||||
| 2022-12-31 | -$105.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | -$202.00M derived: sum of 2 quarters · filed 2025-02-21 | -$432.00M derived: sum of 3 quarters · filed 2025-02-21 | -$578.00M 10-K · filed 2025-02-21 | |
| 2022-09-30 | -$97.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$327.00M derived: sum of 2 quarters · filed 2022-11-03 | -$473.00M 10-Q · filed 2022-11-03 | -$680.00M derived: sum of 4 quarters · filed 2024-02-23 | |
| 2022-06-30 | -$230.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$376.00M 10-Q · filed 2022-08-03 | -$583.00M derived: sum of 3 quarters · filed 2024-02-23 | -$600.00M derived: sum of 4 quarters · filed 2024-02-23 | |
| 2022-03-31 | -$146.00M 10-Q · filed 2022-05-04 | -$353.00M derived: sum of 2 quarters · filed 2024-02-23 | -$370.00M derived: sum of 3 quarters · filed 2024-02-23 | -$392.00M derived: sum of 4 quarters · filed 2024-02-23 | |
| 2021-12-31 | -$207.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | -$224.00M derived: sum of 2 quarters · filed 2024-02-23 | -$246.00M derived: sum of 3 quarters · filed 2024-02-23 | -$296.00M 10-K · filed 2024-02-23 | |
| 2021-09-30 | -$17.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$39.00M derived: sum of 2 quarters · filed 2022-11-03 | -$89.00M 10-Q · filed 2022-11-03 | -$89.00M derived: sum of 4 quarters · filed 2023-02-24 | |
| 2021-06-30 | -$22.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$72.00M 10-Q · filed 2022-08-03 | -$72.00M derived: sum of 3 quarters · filed 2023-02-24 | -$72.00M derived: sum of 4 quarters · filed 2023-02-24 | |
| 2021-03-31 | -$50.00M 10-Q · filed 2022-05-04 | -$50.00M derived: sum of 2 quarters · filed 2023-02-24 | -$50.00M derived: sum of 3 quarters · filed 2023-02-24 | -$50.00M derived: sum of 4 quarters · filed 2023-02-24 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $0.00 derived: sum of 2 quarters · filed 2023-02-24 | $0.00 derived: sum of 3 quarters · filed 2023-02-24 | $0.00 10-K · filed 2023-02-24 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $0.00 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-06 | ||||
| 2019-12-31 | -$1.00M 10-K · filed 2022-02-25 | -$1.20M 10-K · filed 2020-02-27 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-02-26 | ||||
| 2017-12-31 | $0.00 10-K · filed 2020-02-27 | ||||
| 2016-12-31 | $288.00K 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |